Chaffin, Mark http://orcid.org/0000-0002-1234-5562
Papangeli, Irinna
Simonson, Bridget
Akkad, Amer-Denis
Hill, Matthew C.
Arduini, Alessandro http://orcid.org/0000-0002-0038-8741
Fleming, Stephen J. http://orcid.org/0000-0002-1885-4405
Melanson, Michelle
Hayat, Sikander
Kost-Alimova, Maria
Atwa, Ondine
Ye, Jiangchuan
Bedi, Kenneth C. Jr
Nahrendorf, Matthias http://orcid.org/0000-0002-4021-1887
Kaushik, Virendar K.
Stegmann, Christian M.
Margulies, Kenneth B.
Tucker, Nathan R. http://orcid.org/0000-0002-5071-4218
Ellinor, Patrick T. http://orcid.org/0000-0002-2067-0533
Article History
Received: 24 February 2021
Accepted: 27 April 2022
First Online: 22 June 2022
Competing interests
: A.-D.A. is an employee of Bayer US LLC (a subsidiary of Bayer AG) and may own stock in Bayer AG. I.P., S.H. and C.M.S. were full-time employees of Bayer when this work was performed. C.M.S. is now a full-time employee of Vifor Pharma Management. V.K.K. was a co-founder of Dogma Therapeutics and Apolo1 Bio, and is now an employee of Anji Pharmaceuticals. P.T.E. has received sponsored research support from Bayer AG and IBM Health, and he has served on advisory boards or consulted for Bayer AG, MyoKardia and Novartis. K.B.M. has research grant funding from Sanofi-Aventis, USA and has also served on advisory boards for MyoKardia and Pfizer. M.N. has received funds or material research support from Lilly, Alnylam, Biotronik, CSL Behring, GlycoMimetics, GSK, Medtronic, Novartis and Pfizer, as well as consulting fees from Biogen, Gimv, IFM Therapeutics, Molecular Imaging, Sigilon and Verseau Therapeutics. The Broad Institute, Massachusetts General Hospital and Bayer AG have a pending patent application (US application no. 17/669,904) on the identification of activated fibroblasts for the diagnosis and treatment of cardiomyopathy based on the results from this work with M.C., I.P., A.-D.A., C.M.S. and P.T.E. listed as co-inventors. All remaining authors declare no competing interests.